QUININE SULFATE TABLETS:

Final text for revision of The International Pharmacopoeia
(December 2009)

This monograph was adopted at the Forty-third WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2008 for addition to the 4th Edition of The International Pharmacopoeia. With the elaboration of a new monograph for Quinine bisulfate tablets and the need to include additional requirements to differentiate the two sulfate forms of quinine used for tablets formulations, this text was revised and further adopted at the Forty-fourth WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2009.

QUININI SULFAS COMPRESSI
QUININE SULFATE TABLETS

[Note from Secretariat:
- An additional identity test is now included to differentiate between Quinine sulfate tablets and Quinine bisulfate tablets
- Changes from the current monograph are indicated in the text by insert or delete]

Category. Antimalarial.

Storage. Quinine sulfate tablets should be kept in a well-closed container, protected from light.

Additional information. Strength in the current WHO Model list of essential medicines: 300 mg. Strength in the current WHO Model list of essential medicines for children: 300 mg.

300 mg of quinine sulfate (2H₂O) is equivalent to approximately 248.6 mg of anhydrous quinine.

The tablets are coated.
Requirements

Comply with the monograph for “Tablets”.

Definition. Quinine sulfate tablets contain Quinine sulfate. They contain not less than 90.0% and not more than 110.0% of the amount of quinine sulfate [(C\(_{20}\)H\(_{24}\)N\(_2\)O\(_2\))\(_2\),H\(_2\)SO\(_4\),2H\(_2\)O] stated on the label.

Identity tests

- Any two of tests A, B or C may be applied together with tests D and E.

A. Carry out test A.1 or, where UV detection is not available, test A.2.

A.1 Carry out the test as described under 1.14.1 Thin-layer chromatography, using silica gel R6 as the coating substance and a mixture of 20 volumes of toluene R, 12 volumes of ether R and 5 volumes of diethylamine R as the mobile phase. Apply separately to the plate 2 µl of each of the following two solutions in a mixture of 2 volumes of chloroform R and 1 volume of ethanol (~750 g/l) TS. For solution (A) shake a quantity of the powdered tablets containing about 0.1 g of Quinine sulfate with 10 ml, filter, and use the filtrate. If the tablets are sugar coated, remove the coating and powder the tablet cores. For solution (B) use 10 mg of quinine sulfate RS per ml. For solution (C) use 10 mg of quinine sulfate RS and 10 mg of quinidine sulfate RS per ml. After removing the plate from the chromatographic chamber, allow it to dry in air or in a current of cool air and examine the chromatogram in ultraviolet light (254 nm).

The test is not valid unless the chromatogram obtained with solution C shows two clearly separated spots.

The principal spot obtained with solution A corresponds in position, appearance and intensity to that obtained with solution B.

A.2 Carry out the test as described under 1.14.1 Thin-layer chromatography, using the conditions described above under test A.1 but using silica gel R5 as the coating substance. Spray with sulfuric acid/ethanol (~0.05 mol/l) TS and then with potassium iodobismuthate TS2. Examine the chromatogram in daylight.

The test is not valid unless the chromatogram obtained with solution C shows two clearly separated spots.

The principal spot obtained with solution A corresponds in position, appearance and intensity to that obtained with solution B.

B. See the test described below under Related cinchona alkaloids. The retention time of the principal peak in the chromatogram obtained with solution (1) is similar to that in the chromatogram obtained with solution (2).

C. To a quantity of the powdered tablets containing about 15 mg of Quinine sulfate add 50 ml of hydrochloric acid (0.1 mol/l) VS, shake and filter. Dilute 5 ml of the filtrate to
50 ml with the same solvent. The absorption spectrum (1.6) of the resulting solution, when observed between 330 nm and 360 nm, exhibits one maximum at about 347 nm.

D. To a quantity of the powdered tablets containing about 0.25 g of Quinine sulfate add 25 ml of a mixture of 2 volumes of chloroform R and 1 volume of ethanol (~750 g/l) TS, sonicate for about 15 minutes and filter. Evaporate the filtrate to dryness. Stir the residue with 10 ml of ether R and filter. Wash the residue with 10 ml of ether R and dry it at 60°C for 5 hours. The pH of a 10 mg/ml suspension of the residue in water R is 5.5 to 7.0.

E. To a quantity of powdered tablets containing 0.1 g of Quinine sulfate add 10 ml of water R, shake, and filter. The filtrate yields reaction A described under 2.1 General identification tests as characteristic of sulfates.

**Dissolution/Disintegration**

- Either test A or test B may be applied

A. **Dissolution.** Carry out the test as described under 5.5 Dissolution test for solid oral dosage forms, using as the dissolution medium, 500 ml of dissolution buffer, pH 6.8, TS and rotating the paddle at 75 revolutions per minute. At 30 minutes withdraw a sample of 10 ml of the medium through an in-line filter. Measure the absorbance (1.6) of a 1-cm layer of the filtered sample, suitably diluted if necessary, at the maximum at about 330 nm. At the same time measure the absorbance at the maximum at about 330 nm of a suitable solution of quinine sulfate RS in dissolution buffer, pH 6.8, TS, using the same buffer as a blank.

For each of the six tablets tested, calculate the total amount of quinine sulfate \([(C_{20}H_{24}N_{2}O_{2})_2H_2SO_4.2H_2O]\) in the medium. The amount in solution for each tablet is not less than 80% of the amount declared on the label. If the amount obtained for one of the six tablets is less than 80%, repeat the test using a further six tablets; the average amount for all 12 tablets tested is not less than 75% and the amount obtained for no tablet is less than 60%.

B. **Disintegration.** Comply with 5.4 Disintegration test for tablets and capsules, operating the apparatus for 10 minutes. If the tablets do not comply, carry out test A above.

**Related cinchona alkaloids.** Carry out the test as described under 1.14.4 High-performance liquid chromatography, using a stainless steel column (15 cm x 4.6 mm) packed with particles of silica gel, the surface of which has been modified with chemically bonded octadecylsilyl groups (5 µm)\(^1\).

As the mobile phase, use a solution prepared as follows. Dissolve 6.8 g potassium dihydrogen phosphate R and 3.0 g hexylamine R in 900 ml of water R, adjust to pH 3.0 with phosphoric acid (~1440 g/l) TS and dilute to 1000 ml with water R. Mix 920 ml of this solution with 80 ml of acetonitrile R.

\(^{1}\) Luna® has been found suitable
Prepare the following solutions in the solvent consisting of 80 volumes of water R, 20 volumes of acetonitrile R and 0.1 volume of phosphoric acid (~1440 g/l) TS. For solution (1) weigh and powder 20 tablets or, if the tablets are sugar coated, remove the coating and powder the tablet cores. Transfer a quantity of the powder containing about 60 mg of Quinine sulfate to a 20-ml volumetric flask, add 15 ml of the solvent, sonicate for about 5 minutes, allow to cool to room temperature and make up to volume using the solvent. Filter a portion of this solution through a 0.45-µm filter, discarding the first few ml of the filtrate. For solution (2) dissolve about 30 mg of quinine sulfate RS in 10 ml of the solvent. For solution (3) dissolve about 15 mg of quinidine sulfate RS in 5 ml of solution (2).

Operate with a flow rate of 1.3 ml per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of about 316 nm.

Inject separately 10 µl each of solution (1), (2) and (3) in the chromatographic system and record the chromatograms for 2.5 times the retention time of the quinine (principal) peak in solution (2).

In the chromatogram obtained with solution (3), the following peaks are eluted at the following relative retention with reference to quinine (retention time about 10 minutes): quinidine about 0.8; dihydroquinidine about 1.2; dihydroquinine about 1.5. The test is not valid unless the resolution between the peaks due to quinidine and quinine and that between the peaks due to quinine and dihydroquinidine is at least 1.5. The chromatograms obtained with solutions (1), (2) and (3) may also show a peak due to cinchonidine eluting at a relative retention of about 0.6 with reference to quinine.

Calculate the percentage content of the related substances in the chromatogram obtained with solution (1) by normalisation. The content of dihydroquinine is not more than 10%, the content of cinchonidine not more than 5% and the content of any other related substance not more than 2.5%. The sum of the related substances is not more than 15%. Disregard any related substance of content less than 0.1%.

**Assay.** Weigh and powder 20 tablets. Gently stir a quantity of the powder containing about 0.20 g of Quinine sulfate, accurately weighed, in 40 ml of acetic anhydride R for 15 minutes. Titrate with perchloric acid (0.1 mol/l) VS, determine the end point potentiometrically as described under 2.6 Non-aqueous titration, Method A. Each ml of perchloric acid (0.1 mol/l) VS is equivalent to 26.10 mg of quinine sulfate [(C_{20}H_{24}N_{2}O_{2})_{2},H_{2}SO_{4},2H_{2}O].

**Impurities**

A. quinidine
B. $R = \text{CH}=\text{CH}_2$, $R' = \text{H}$: (R)-[(2S,5R)-ethenyl-1-azabicyclo[2.2.2]oct-2-yl](quinolin-4-yl)methanol (cinchonidine)

C. $R = \text{C}_2\text{H}_5$, $R' = \text{OCH}_3$: (R)-[(2S,5R)-ethyl-1-azabicyclo[2.2.2]oct-2-yl](6-methoxyquinolin-4-yl)methanol (dihydroquinine)

****

New reagents to be added to Ph.Int

Sulfuric acid/ethanol ($\sim 0.05 \text{ mol/l}$)

Carefully add 4.9 g of sulfuric acid ($\sim 1760 \text{ g/l}$) TS to about 800 ml ethanol ($\sim 750 \text{ g/l}$) TS, while mixing gently, and dilute to 1000 ml with ethanol ($\sim 750 \text{ g/l}$) TS.

***